HydRx Farms Ltd, a biopharmaceutical company conducting research and product development for extracts and formulations related to medical cannabinoids and their derivatives, announced yesterday that the United States Patent and Trademark Office has granted US Patent Number 10,143,706, entitled 'Decarboxylated Cannabis Resins, Uses Thereof and Methods of Making Same.'

The patent offers intellectual property protection for Scientus' decarboxylation method for extraction and activation of Active Pharmaceutical Ingredient from natural cannabis plant materials.

Har Grover, chairman and CEO of Scientus, said, 'First mover advantage only matters if one can protect it. The granting of this patent is an important step to protect Scientus Pharma's competitive advantage through product innovation. Our method for extracting and activating cannabis API is unique in the industry and fundamental to our growth strategy. Our method provides intermediary resin that is more than 99 percent activated for THC and CBD, which maximises the potency and bioavailability of the API. Our process also yields batches with consistent product profiles, enabling cannabinoid products to reach pharmaceutical-grade standards, rather than just medical-grade.'